


令和 3 年 6 月 14 日

履 歴 書

フリガナ	イデ カズキ				
氏 名	井出 和希	性 別	男	平成 1 年 3 月 25 日生 (満 32 歳)	

E-mail: ide.kazuki.2r@kyoto-u.jp

学 歴

年 月	事 項
2007 年 3 月	私立 星陵高等学校卒業
2011 年 3 月	静岡県立大学薬学部卒業, 学士(薬学)
2013 年 3 月	静岡県立大学大学院薬学研究科 博士前期課程修了, 修士(薬科学)
2016 年 9 月	静岡県立大学 薬食生命科学総合学府 博士後期課程早期修了, 博士(薬科学)

職 歴

年 月	事 項
2015 年 4 月	日本学術振興会 特別研究員(静岡県立大学, ~2016 年 9 月)
2016 年 10 月	京都大学 学際融合教育研究推進センター 特定助教(~2019 年 3 月)
2016 年 10 月	静岡県立大学 薬学部 医薬品情報解析学分野 客員共同研究員(~現在)
2016 年 12 月	リアルワールドデータ株式会社 技術指導(~2019 年 3 月)
2019 年 4 月	京都大学 学際融合教育研究推進センター 研究員(~2020 年 3 月)
2020 年 4 月	京都大学 iPS 細胞研究所 上廣倫理研究部門 特定助教(~2021 年 4 月)
2021 年 4 月	大阪大学 感染症総合教育研究拠点 科学情報・公共政策部門 特任准教授
2021 年 4 月	大阪大学 社会技術共創研究センター (ELSI センター) 特任准教授(兼担)

学 会 及 び 社 会 に お け る 活 動 等

所属学会	日本薬学会、日本薬学教育学会、日本学校保健学会、日本薬剤疫学会 日本臨床疫学会、日本臨床薬理学会、日本神経学会、日本神経科学学会
資格	薬剤師(第 475348 号)

賞 罰

年 月	事 項
2014 年 3 月	茶学術研究会 学術奨励賞, 日本薬学会 第 134 年会 講演ハイライト
2014 年 9 月	ESPEN(欧州臨床栄養代謝学会議)2014 OUTSTANDING ABSTRACT
2018 年 8 月	Nutrition: Outstanding Contribution in Reviewing(Elsevier)
2018 年 9 月	日本臨床疫学会 第 2 回年次学術大会 優秀ポスター賞
2018 年 9 月	Publons' 2018 Global Peer Review Awards 「Top 1% in Field」
2019 年 3 月	Art Innovation 2019: Junji Ito Award
2019 年 9 月	Top Peer Reviewer Award 2019 in Cross-Field(世界上位 1%, Web of Science)

研究業績目録

(a) 原著論文

(欧文)

1. Kunitomi Y, Nakashima M, Seki T, **Ide K**, Kawakami K. Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: An observational study using a Japanese administrative claims database. *Support Care Cancer*. 2021; **29** (7): 3951-3959.
2. **Ide K**, Matsuoka N, Fujita M. Ethical aspects of brain organoid research in news reports: An exploratory descriptive analysis. *Medicina (Kaunas)*. 2021; **57**(6): 532 (6 pp).
3. **Ide K**, Koshiba H, Hawke P, Fujita M. Guidelines are urgently needed for the use of preprints as a source of information. *J Epidemiol*. 2021; **31**: 97-99.
4. **Ide K**, Fujiwara T, Shimada N, Tokumasu H. Influence of acetaminophen on renal function: A longitudinal descriptive study using a real-world database. *Int Urol Nephrol*. 2021; **53**: 129-135.
5. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Ono Y, Furukawa TA. Age-related changes in item responses to the Patient Health Questionnaire-9: Evidence from the National Health and Nutrition Examination Survey. *Front Psychiatry*. 2020; **11**: 723 (9 pp).
6. Aoki Y, Kawasaki Y, **Ide K**, Shimizu Y, Sato S, Yokoyama J. Landiolol hydrochloride for prevention of atrial fibrillation during esophagectomy: A randomized controlled trial. *JA Clin Rep*. 2020; **6**: 34 (9 pp).
7. Honjo Y, **Ide K**, Takechi H. Use of day services improved cognitive function in patients with Alzheimer's disease. *Psychogeriatrics*. 2020; **20**: 620-624.
8. Nagai K, **Ide K**, Kawasaki Y, Tanaka-Mizuno S, Seto K, Iwane S, Eguchi Y, Kawakami K. Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan. *Hepatology Res*. 2020; **50**: 542-556.
9. **Ide K**, Yoshida S, Kimura T, Oita Y, Kawakami K. The general understanding and perceptions of the practical use of school health records: A questionnaire survey of parents from seven local municipalities in Japan. *School Health*. 2020; **16**: 33-42.
10. Honjo Y, **Ide K**, Takechi H. Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease. *Geriatr*

Gerontol Int. 2020; **20**: 324-328.

11. Nagai K, Matsubayashi K, **Ide K**, Seto K, Kawasaki Y, Kawakami K. Factors influencing placebo responses in rheumatoid arthritis clinical trials: a meta-analysis of randomized, double-blind, placebo-controlled studies. *Clin Drug Invest.* 2020; **40**: 197-209.
12. Joo WJ, **Ide K**, Nishiyama K, Seki T, Tanaka H, Tsuchiya J, Ito N, Yoshida K, Kawakami K. Prediction of the neurological outcome using regional cerebral oxygen saturation in patients with extracorporeal cardiopulmonary resuscitation after out-of-hospital cardiac arrest: A multicenter retrospective cohort study. *Acute Med Surg.* 2020; **7**: e491 (7 pp).
13. Nakashima M, **Ide K**, Kawakami K. Laparoscopic versus open repair for inguinal hernia in children: a retrospective cohort study. *Surg Today.* 2019; **49**: 1044-1050.
14. Yonekura H, **Ide K**, Kanazawa Y, Takeda C, Nakamori Y, Matsunari Y, Sakai M, Kawakami K, Kamei M. Use of preoperative haemostasis and ABO blood typing tests in children: A retrospective observational study using a nationwide claims database in Japan. *BMJ Open.* 2019; **9**(11): e032306 (8 pages).
15. Peter Brown, **RELISH Consortium**, Yaoqi Zhou. Large expert-curated database for benchmarking document similarity detection in biomedical literature search. *Database.* 2019; **2019**: baz085 (66 pages). (contributed as a RELISH Consortium member)
16. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Ono Y, Furukawa TA. Responses to depressive symptom items exhibit a common mathematical pattern across the European populations. *Sci Rep.* 2019; **9**: 14923 (9 pages).
17. Aoki Y, **Ide K**, Nakajima F, Kawasaki Y, Fujita Y, Morimoto E, Yokoyama J. Esophagectomy surgical Apgar score may not be associated with postoperative morbidity. *Semin Thorac Cardiovasc Surg.* 2019; **31**(3): 574-580.
18. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Ono Y, Furukawa T. Distribution of psychological distress is stable in recent decades and follows an exponential pattern in the US population. *Sci Rep.* 2019; **9**: 11982 (10 pages).
19. Mizuno K, Takeuchi M, Kanazawa Y, Kitamura M, Ide K, Omori K, Kawakami K. Recurrent laryngeal nerve paralysis after thyroid cancer surgery and intraoperative nerve monitoring. *Laryngoscope.* 2019; **129**(8): 1954-1960.
20. Nakashima M, **Ide K**, Kawakami K. Comparison of standard initial dose and reduced initial dose regorafenib for colorectal cancer patients: A retrospective

- cohort study. *Target Oncol.* 2019; **14**(3): 295-306.
21. Tomitaka S, Kawasaki Y, **Idé K**, Akutagawa M, Ono Y, Furukawa TA. Further evidence that item responses on the Kessler Psychological Distress Scale exhibit the characteristic pattern in the general population. *Heliyon.* 2019; **5**(3): e01387 (15 pages).
 22. Kawasoe S, **Idé K**, Usui T, Kubozono T, Yoshifuku S, Miyahara H, Maenohara S, Ohishi M, Kawakami K. Distribution and characteristics of hypouricemia within the Japanese general population: A cross-sectional study. *Medicina.* 2019; **55**: 61 (14 pages).
 23. Joo WJ, **Idé K**, Kawasaki Y, Chikashi Takeda C, Seki T, Usui T, Kawakami K. Effectiveness and safety of early enteral nutrition for patients who received targeted temperature management after out-of-hospital cardiac arrest. *Resuscitation.* 2019; **135**: 191-196.
 24. Yonekura H, **Idé K**, Onishi Y, Nahara I, Takeda C, Kawakami K. Preoperative echocardiography for patients with hip fractures undergoing surgery: A retrospective cohort study using a nationwide database. *Anesth Analg.* 2019; **128**(2): 213-220.
 25. **Idé K**, Matsuoka N, Yamada H, Furushima D, Kawakami K. Effects of tea catechins on Alzheimer's disease: Recent updates and perspectives. *Molecules* 2018; **23**: 2357.
 26. **Idé K**, Takeuchi M, Seki T, Kawakami K. Effect of regular exercise and functional beverages on changes in body weight and waist circumference in healthy Japanese subjects. *Medicina (Kaunas)* 2018; **54**: 64.
 27. Miki R, Becker CB, **Idé K**, Kawakami K. Timing and facilitation of advanced directives in Japan. *Arch Gerontol Geriatr.* 2018; **79**: 83-87.
 28. Tomitaka S, Kawasaki Y, **Idé K**, Akutagawa M, Ono Y, Furukawa TA. Distribution of item responses and total item scores for the Center for Epidemiologic Studies Depression Scale (CES-D): data from the Irish Longitudinal Study on Ageing (TILDA). *PLoS ONE.* 2018; **13**: e0202607.
 29. Tomitaka S, Kawasaki Y, **Idé K**, Akutagawa M, Ono Y, Furukawa TA. Stability of the distribution of Patient Health Questionnaire-9 Scores against age in the general population: Data from the national health and nutrition examination survey. *Front Psychiatry.* 2018; **9**: 390
 30. Furushima D, **Idé K**, Yamada H. Effect of tea catechins on influenza infection and

the common cold with a focus on epidemiological/clinical studies. *Molecules*. 2018; **3**: 1795.

31. **Ide K**, Seto K, Usui T, Tanaka S, Kawakami K. Correlation between dental conditions and comorbidities in an elderly Japanese population: A cross-sectional study. *Medicine*. 2018; **97**: e11075.
32. Iketani R, **Ide K**, Yamada H, Kawasaki Y, Masaki N. Regional differences in the safety of telaprevir-based triple therapy for chronic hepatitis C in Japan: a retrospective pilot cohort study. *Jpn J Drug Inform*. 2018; **20**: 57-65
33. Usui T, Funagoshi M, Seto K, **Ide K**, Tanaka S, Kawakami K. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: A claims database analysis. *Arch Osteoporos*. 2018; **13**: 54.
34. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Yamada H, Ono Y, Furukawa TA. Distributional patterns of item responses and total scores on the PHQ-9 in the general population: data from the National Health and Nutrition Examination Survey. *BMC Psychiatry*. 2018; **18**: 108.
35. Yoshida S, **Ide K**, Takeuchi M, Kawakami K. Prenatal and early-life antibiotic use and risk of childhood asthma: A retrospective cohort study. *Pediatr Allergy Immunol*. 2018; **29**: 490-495.
36. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Yamada H, Furukawa TA. Exponential distribution of total depressive symptom scores in relation to exponential latent trait and item threshold distributions: a simulation study. *BMC Res Notes*. 2017; **10**: 614.
37. **Ide K**, Yonekura H, Kawasaki Y, Kawakami K. Influence of institution-based factors on preoperative blood testing prior to lowrisk surgery: a Bayesian generalized linear mixed approach. *Comput Math Methods Med*. 2017; **2017**: 3624075.
38. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Yamada H, Ono Y, Furukawa TA. Item Response Patterns on the Patient Health Questionnaire-8 (PHQ-8) in a Nationally Representative Sample of US Adults. *Front Psychiatry*. 2017; **8**: 251.
39. Yonekura H, Seto K, **Ide K**, Kawasaki Y, Tanaka S, Nahara I, Takeda C, Kawakami K. Preoperative blood tests conducted prior to low-risk surgery in Japan: a retrospective observational study using a nationwide insurance claims database. *Anesth Analg*. 2017; **126**: 1633-1640.
40. Yonekura H, **Ide K**, Seto K, Kawasaki Y, Tanaka S, Nahara I, Takeda C,

- Kawakami K. Preoperative pulmonary function tests before low-risk surgery in Japan: a retrospective cohort study using a claims database. *J Anesth.* 2017; **32**: 23-32.
41. Akutagawa M, Idé K, Kawasaki Y, Yamanaka M, Iketani R, Yamada H, Masaki N. Safety profile of telaprevir-based triple therapy in elderly patients: A real-world retrospective cohort study. *Biol Pharm Bull.* 2017; **40**: 1525-1529.
 42. Tomitaka S, Furukawa TA, Kawasaki Y, Idé K, Akutagawa M, Ono Y, Yamada H. Characteristic distribution of the total and individual item scores on the Kessler Screening Scale for Psychological Distress (K6) in US adults. *BMC Psychiatry.* 2017; **17**: 290.
 43. Sakakibara I, Idé K, Kawasaki Y. Feasibility of Analysis Data Model conversion of national center biobank network catalog data. *Jpn J Clin Pharmacol Ther.* 2017; **48**: 95-98.
 44. Chiba T, Sato Y, Kobayashi E, Idé K, Yamada H, Umegaki K. Behaviors of consumers, physicians and pharmacists in response to adverse events associated with dietary supplement use. *Nutr J.* 2017; **16**: 18.
 45. Kitagawa M, Idé K, Kawasaki Y, Niwata S, Matsushita K, Kaji M, Umegaki K, Yamada H. Reliability of the evaluation methods used to assess a causal relationship between dietary supplement intake and changes in adverse events. *Jpn J Drug Inform.* 2017; **19**: 24-31.
 46. Idé K, Kawasaki Y, Iketani R, Masaki N. Risk factors for treatment discontinuation caused by adverse events when using telaprevir, peginterferon, and ribavirin to treat chronic hepatitis C: A real-world retrospective cohort study. *Biol Pharm Bull.* 2017; **40**: 645-649.
 47. Doi M, Idé K, Kawasaki Y. Bayesian indexes of superiority and equivalence and the p- value of the F-test for the variances of normal distributions. *Jpn J Biometrics.* 2017; **38**: 1-16.
 48. Akutagawa M, Kawasaki Y, Kawasaki A, Idé K, Yamada H, Masaki N. Cost-outcome description of PEG-IFN- α 2b + RBV for hepatitis C: results based on the interferon database. *Biol Pharm Bull.* 2017; **40**: 594-597.
 49. Iketania R, Idé K, Yamada H, Kawasaki Y, Masaki N. The safety profile of telaprevir-based triple therapy in clinical practice: a retrospective cohort study. *Biol Pharm Bull.* 2017; **40**: 687-692.
 50. Tomitaka S, Kawasaki Y, Idé K, Akutagawa M, Yamada H, Furukawa TA, Ono Y.

Pattern analysis of total item score and item response of the Kessler Screening Scale for Psychological Distress (K6) in a nationally representative sample of US adults. *PeerJ*. 2017; **5**: e2987.

51. **Ide K**, Kawasaki Y, Akutagawa M, Yamada H. Effects of green tea gargling on the prevention of influenza infection: An analysis using Bayesian approaches. *J Altern Complement Med*. 2017; **23**: 116-120.
52. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Yamada H, Furukawa TA, Ono Y. Relationship between item responses of negative affect items and the distribution of the sum of the item scores in the general population. *PLoS ONE*. 2016; **11**: e0165928.
53. **Ide K**, Yamada H, Takuma N, Kawasaki Y, Morohoshi H, Takenaka A, Kaihatsu K. Effects of catechin-treated masks on the prevention of influenza infection: an exploratory randomized study. *Jpn J Clin Pharmacol Ther*. 2016; **47**: 229-234.
54. Tomitaka S, Kawasaki Y, **Ide K**, Akutagawa M, Yamada H, Furukawa TA, Ono Y. Boundary curves of individual items in the distribution of total depressive symptom scores approximate an exponential pattern in a general population. *PeerJ*. 2016; **4**: e2566.
55. **Ide K**, Sato I, Imai T, Hawke P, Yamada H, Kawasaki Y, Masaki N. Comparison of the safety profiles of pegylated interferon α -2a and α -2b administered in combination with ribavirin for chronic hepatitis C infection: A real-world retrospective cohort study. *Biol Pharm Bull*. 2016; **39**: 2060-2065.
56. Kawasaki Y, Doi M, **Ide K**, Miyaoka E. A Bayesian non-inferiority index for two Poisson parameters. *Cogent Math*. 2016; **3**: 1229373.
57. **Ide K**, Kawasaki Y, Akutagawa M, Yamada H. Effects of green tea gargling on the prevention of influenza infection: An analysis using Bayesian approaches. *J Altern Complement Med*. 2017; **23**: 116-120.
58. **Ide K**, Yamada H, Kawasaki Y, Yamanaka M, Kawakami N, Katsuyama Y, Yoshida H, Kim K, Shiosaki E, Sonoda A, Umegaki K, Harada K. Peripheral vitamin C levels in Alzheimer's disease: A cross-sectional study. *J Nutr Sci Vitaminol (Tokyo)*. 2016; **62**: 432-436.
59. **Ide K**, Kawasaki Y, Akutagawa M, Yamada H, Masaki N. Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan in both genotype 1 and genotype 2: A retrospective cohort study. *Biol Pharm Bull*. 2016; **39**: 1538-1543.

60. **Ide K**, Yamada H, Kawasaki Y, Noguchi H, Kitagawa M, Chiba T, Kagawa Y, Umegaki K. Reporting of adverse events related to dietary supplements to a public health center by medical staff: a survey of clinics and pharmacies. *Ther Clin Risk Manag.* 2016; **12**: 1403-1410.
61. Kawasaki Y, Doi M, **Ide K**, Miyaoka E. Bayesian index to compare assumed survival functions of two hazards following exponential distributions. *Cogent math.* 2016; **3**: 1193927.
62. **Ide K**, Yamada H, Kawasaki Y. Effect of gargling with tea and ingredients of tea on the prevention of influenza infection: a meta-analysis. *BMC Public Health.* 2016; **16**: 396.
63. Tamano H, **Ide K**, Adlard P, Bush A, Takeda A. Involvement of hippocampal excitability in amyloid β -induced Behavioral and Psychological Symptoms of Dementia. *J Toxicol Sci.* 2016; **41**: 449-57.
64. **Ide K**, Yamada H, Takuma N, Kawasaki Y, Harada S, Nakase J, Ukawa Y, Sagesaka YM. Effects of green tea consumption on cognitive dysfunction in an elderly population: A randomized placebo-controlled study. *Nutr J.* 2016; **15**: 49.
65. Tamano H, Enya Y, **Ide K**, Takeda A. Influences of Yokukansankachimpihange on aggressive behavior of zinc-deficient mice and actions of the ingredients on excessive neural exocytosis in the hippocampus of zinc-deficient rats. *Exp Anim.* 2016, 2016; **65**: 353-361.
66. **Ide K**, Kawasaki Y, Yamada H, and Masaki N. Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study. *Drug Des Devel Ther.* 2016; **10**: 1217-1223.
67. Tomitaka S, Kawasaki Y, **Ide K**, Yamada H, Miyake K, Ono Y. Distributions of total depressive symptoms scores and negative depressive symptom items in a sample of Japanese employees. *PLoS One.* 2016; **11**: e0147577.
68. Tomitaka S, Kawasaki Y, **Ide K**, Yamada H, Furukawa T, Ono Y. Age-related changes in the distributions of depressive symptom items in the general population: Cross-sectional study using a mathematical model. *PeerJ.* 2016; **4**: e1547.
69. Sato I, Y. Kawasaki Y, **Ide K**, I. Sakakibara, Konomura K, Yamada H, Tanaka Y. Clinical Data Interchange Standards Consortium Standardization of Biobank Data: A Feasibility Study. *Biopreserv Biobank.* 2016; **14**: 45-50.
70. **Ide K**, Yamada H, Kitagawa M, Kawasaki Y, Buno Y, Matsushita K, Kaji M,

Fujimoto K, Waki M, Nakashima M, Umegaki K. Methods for estimating causal relationships of adverse events with dietary supplements. *BMJ Open*. 2015; **5**: e009038.

71. **Ide K**, Yamada H, Umegaki K, Mizuno K, Kawakami N, Hagiwara Y, Matsumoto M, Yoshida H, Kim K, Shiosaki E, Yokochi T, Harada K. Lymphocyte vitamin C level as a potential biomarker for the progression of Parkinson's disease. *Nutrition*. 2015; **31**: 406-408.
72. **Ide K**, Yamada H, Takuma N, Park M, Wakamiya N, Nakase J, Ukawa Y, Sagesaka Y. M. Green tea consumption effects cognitive dysfunction in the elderly: A pilot study. *Nutrients*. 2014; **6**: 4032-4042.
73. **Ide K**, Yamada H, Matsushita K, Ito M, Nojiri K, Toyoizumi K, Matsumoto K, Sameshima Y. Effects of green tea gargling on the prevention of influenza infection in high school students: A randomized controlled study. *PLoS One*. 2014; **9**: e96373.
74. Takeda A, Iwaki H, **Ide K**, Tamano H, Oku N. Therapeutic effect of yokukansan on social isolation-induced aggressive behavior of zinc-deficient and pair-fed mice. *Brain Res Bull*. 2012; **87**: 551-555.
75. Takeda A, Suzuki M, Tamano H, Takada S, **Ide K**, Oku N. Involvement of glucocorticoid-mediated Zn²⁺ signaling in attention of hippocampal CA1 LTP by acute stress. *Neurochem Int*. 2012; **60**: 394-399.

(和文)

76. 及川久遠, **井出和希**, 細野智之, 芥川麻衣子, 川崎洋平, 渡辺 美智子. 高校数学における統計教育の教材開発とその実践. *統計数理*. 2018; **66**(1): 121-134.
77. 千葉剛, 小林悦子, 佐藤陽子, **井出和希**, 池谷怜, 山田浩, 梅垣敬三. 健康食品の利用が関連した被害通報の実態調査—消費者及び医師・薬剤師を対象としたインターネット調査—. *食品衛生学雑誌*. 2017; **58**: 234-240.
78. **井出和希**, 吉田都美, 尾板靖子, 川上浩司. 学校健診データの利活用に対する認識と理解: 保護者を対象としたアンケート調査. *学校保健研究*. 2017; **59**: 341-346.
79. 松坂昌宏, 小林豊, 萩原紫織, 望月真太郎, 高田正弘, **井出和希**, 川崎洋平, 山田浩, 諏訪紀衛, 鈴木高弘, 横山美智江, 伊藤譲, 北村修, 小野孝彦, 米村克彦. 静岡県の病院・薬局薬剤師による腎臓病薬物療法への取り組み: 現状と課題に関するアンケート調査. *日本腎臓病薬物療法学会誌*. 2017; **6**: 15-27.
80. 内山吉彬, 川崎洋平, **井出和希**, 野口真里茄, 曾我俊幸, 山田浩. 静岡県内における生物統計コンサルテーションの現状: 医療機関を対象としたアンケート. *臨床薬理*.

2016; **47**: 209-217.

81. 小林豊, 吉岡雅代, 稲葉達也, 鈴木豊秀, 榎間昌哲, **井出和希**, 川崎洋平, 山田浩, 北村修, 米村克彦. 保存期慢性腎臓病における沈降炭酸カルシウムと胃酸分泌抑制薬の相互作用を事例とした薬剤師の情報提供と医師の処方意識の変化. *日本腎臓病薬物療法学会誌*. 2015; **4**: 31-38. **井出和希**, 幾見泰洋, 木内亜弥, 曾根順子, 小島真, 山田浩. お薬手帳の再持参率を指標とした手帳活用度の調査. *医薬品情報学*. 2014; **16**: 201-205.
82. 一丸佳代#, **井出和希**#, 小野彩奈, 北川護, 成島大智, 松本圭司, 梅垣敬三, 山田浩. 健康食品の摂取に伴う有害事象の因果関係評価のための樹枝状アルゴリズムの改変. *臨床薬理*, 2013; **44**: 405-410. (#equal contribution)
83. **井出和希**, 野尻 桂, 長坂しおり, 一丸佳代, 豊泉樹一郎, 松本圭司, 山田浩. 薬学部卒前教育における臨床研究方法論の習得-チュートリアル形式による医療統計学の指導と実践-. *Clin Res Prof*. 2013; **35-36**: 60-64.

(b) 総説

(欧文)

84. **Ide K**, Matsuoka N, Kawakami K. Is the use of proton-pump inhibitors a risk factor for Alzheimer's disease? Molecular mechanisms and clinical implications. *Curr Med Chem*. 2018; **25**: 2166-2174.
85. **Ide K**, Kawasaki Y, Kawakami K, Yamada H. Anti-influenza virus effects of catechins: A molecular and clinical review. *Curr Med Chem*. 2016; **23**: 4773-4783.
86. **Ide K**, Yamada H. Clinical benefits of green tea consumption for cognitive dysfunction. *PharmaNutrition*. 2015; **3**:136-145.

(和文)

87. **井出和希**, 川上浩司. ライフコースデータとRWDの利活用ノウハウ. *PHARM STAGE*. 2018; **10**: 44-51.
88. **井出和希**, 川崎洋平, 山田浩. 茶の効用:臨床におけるエビデンス. *機能性食品と薬理栄養*. 2016; **9**: 366-371.
89. **井出和希**, 山田浩. 緑茶の認知機能改善効果. *食品と科学*. 2014; **56**: 67-73.
90. 諸星晴香, **井出和希**, 原田翔平, 藤井貞子, 中原あつ子, 鈴木剛士, 田熊規方, 山田浩. 研究者主導臨床試験でのデータ入力におけるエラー割合の検討. *薬理と治療*. 2014; **42**: 904-907.
91. **井出和希**, 山田浩. 緑茶カテキンの認知症に対する抑制効果. *Functional Food*. 2014; **8**: 31-35.
92. **井出和希**, 山田浩. かぜ症候群 受診勧奨のポイント. *日本薬剤師会雑誌*. 2014; **66**:

769-773.

(c) 著書

(欧文)

93. **Ide K**, Kawasaki Y, Kawakami K, Yamada H. Effects of bioactive components of green tea on Alzheimer's disease and their structure-activity relationships. In: Attar-Rahman, eds. *Studies in Natural Products Chemistry* (vol. 56). St. Louis, Mo.: Elsevier, 2018, 151-172.

(和文)

94. 宮野公樹, **井出和希**, 重田眞義. 京大 100 人論文—第 5 回学内良縁創出プロジェクト—(成果報告冊子), 京都大学 学際融合教育研究推進センター発行(184 pp).
95. 漆原尚巳, 田中司郎, 川上浩司(監修); **井出和希**, 古閑 晃(監訳). *ストロムの薬剤疫学-Textbook of Pharmacoepidemiology-*. 東京: 南山堂, 2019.
96. **井出和希**, 山田浩. 16. てんかん. In. 藤村昭夫, 後藤伸之, eds. *エキスパートが教える薬の使い方×エビデンスの調べ方*. 東京: 株式会社じほう, 2017: 142-154.
97. **井出和希**. 分散分析・多重比較. In: 山田浩, 磯野修作, 渡辺秀章, eds. *生物統計・臨床研究デザイン テキストブック*. 東京, 日本: メディカルパブリケーションズ, 2015: 88-99.

(d) その他

(欧文)

98. Nifli AP, Tsolaki M, Tournoy J, **Ide K**. Editorial: Cognitive impairment: Therapy momentum in the continuum of life. *Front Pharmacol*. 2021, *in press*.
99. **Ide K**, Kawakami K. How do you treat asthma in your practice? *Med Acupunct*. 2018; **30**:100-112.
100. **Ide K**, Kawakami K. How do you treat upper respiratory infections in the elderly in your practice? *Med Acupunct*. 2017; **29**: 105-113.
101. Shimada Y, Nakagawa Y, **Ide K**, Sato I, Hagiwara S, Yamada H, Kawasaki Y, Maruoka Y. Importance of eliminating potential dental focal infection before the first cycle of chemotherapy in patients with hematologic malignancy. *Support Care Cancer*. 2017; **25**: 1379-1381.
102. **Ide K**, Park M, Yamada H. The effect of green tea with exceptionally high catechin content on nadolol plasma concentration. *Clin Pharmacol Ther*. 2014; **95**: 588.

(和文)

103. 今井匠, **井出和希**. 毒舌妻と統計家 臨床試験論文を読んでみる「第7回: 新型コロナ

- ウイルス感染症のワクチンができるまで(後編)」。薬局. 2021, **72** (7): 153-161.
104. 今井匠, 井出和希. 毒舌妻と統計家 臨床試験論文を読んでも「第6回:新型コロナウイルス感染症のワクチンができるまで(前編)」。薬局. 2021, **72** (6): 135-146.
105. 今井匠, 井出和希. 毒舌妻と統計家 臨床試験論文を読んでも「第5回: Kaplan-Meier 曲線と患者の半分の回復までの時間」。薬局. 2021; **72** (5): 102-112.
106. 今井匠, 井出和希. 毒舌妻と統計家 臨床試験論文を読んでも「第4回: 介入と曝露, ピコとペコ」。薬局. 2021; **72** (3): 503-509.
107. 今井匠, 井出和希. 毒舌妻と統計家 臨床試験論文を読んでも「第3回: ハザード比, 信頼区間, 統計学的に有意」。薬局. 2021; **72** (2): 147-154.
108. 井出和希. 倫理の窓から見た iPS 細胞: 新型コロナウイルス感染症と論文を「審査する」営み. CiRA ニュースレター. 2021: 44; 9.
109. 今井匠, 井出和希. 毒舌妻と統計家 臨床試験論文を読んでも「第2回: 盲検化, 主要評価項目, ITT」。薬局. 2020; **71**: 131-140.
110. 今井匠, 井出和希. 毒舌妻と統計家 臨床試験論文を読んでも「第1回: ランダムに分ける」。薬局. 2020; **71**: 89-94.
111. 井出和希. 第二報告「デジタルヘルス時代の疫学と人間の行方」。アジア的人間観から見たサイバー空間における民主主義 News Letter. 2020; No.2: 26-37.
112. 井出和希. 市民・自治体の皆様との相互理解の形成を目指して—連携7自治体を対象としたアンケート調査から分かったこと—。(一社)健康・医療・教育情報評価推進機ニュースレター. 2018, 13.
113. 井出和希. 市民・自治体の皆様との相互理解の形成を目指して—アンケート調査から分かったこと—。(一社)健康・医療・教育情報評価推進機ニュースレター. 2017: 7-8
114. 井出和希, 川上浩司. 自治体の持つ学校健診情報の可視化とその利用に向けての基盤構築. SciREX Quarterly. 2017.
115. 北川護, 井出和希, 成島大智, 山田浩. 健康食品の安全性をめぐる最近の話題. Functional Food. 2014; **8**: 52-57.